DB:G49N

Stock Analysis Report

Executive Summary

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.

Rewards

Revenue is forecast to grow 39.06% per year

Risk Analysis

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

Latest financial reports are more than 6 months old

+ 1 more risk


Snowflake Analysis

Mediocre balance sheet with limited growth.

Share Price & News

How has GenSight Biologics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: G49N's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

6.5%

G49N

1.0%

DE Biotechs

2.0%

DE Market


1 Year Return

68.0%

G49N

6.8%

DE Biotechs

15.1%

DE Market

Return vs Industry: G49N exceeded the German Biotechs industry which returned 6.2% over the past year.

Return vs Market: G49N exceeded the German Market which returned 15% over the past year.


Shareholder returns

G49NIndustryMarket
7 Day6.5%1.0%2.0%
30 Day-6.0%-1.2%1.0%
90 Day208.4%7.4%3.8%
1 Year68.0%68.0%7.1%6.8%18.6%15.1%
3 Year-50.9%-50.9%48.3%46.6%16.8%6.6%
5 Yearn/a11.4%9.0%23.7%6.7%

Price Volatility Vs. Market

How volatile is GenSight Biologics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is GenSight Biologics undervalued compared to its fair value and its price relative to the market?

6.69x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate G49N's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate G49N's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: G49N is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: G49N is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate G49N's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: G49N is overvalued based on its PB Ratio (6.7x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is GenSight Biologics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

10.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: G49N is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: G49N is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: G49N is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: G49N's revenue (39.1% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: G49N's revenue (39.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if G49N's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has GenSight Biologics performed over the past 5 years?

-30.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: G49N is currently unprofitable.

Growing Profit Margin: G49N is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: G49N is unprofitable, and losses have increased over the past 5 years at a rate of -30.2% per year.

Accelerating Growth: Unable to compare G49N's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: G49N is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: G49N has a negative Return on Equity (-255.34%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is GenSight Biologics's financial position?


Financial Position Analysis

Short Term Liabilities: G49N's short term assets (€25.2M) exceed its short term liabilities (€8.7M).

Long Term Liabilities: G49N's short term assets (€25.2M) exceed its long term liabilities (€7.0M).


Debt to Equity History and Analysis

Debt Level: G49N's debt to equity ratio (23.1%) is considered satisfactory.

Reducing Debt: G49N's debt to equity ratio has increased from 2.3% to 23.1% over the past 5 years.


Balance Sheet

Inventory Level: G49N has a low level of unsold assets or inventory.

Debt Coverage by Assets: G49N's debt is covered by short term assets (assets are 7.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: G49N has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: G49N has less than a year of cash runway if free cash flow continues to reduce at historical rates of -30% each year


Next Steps

Dividend

What is GenSight Biologics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate G49N's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate G49N's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if G49N's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if G49N's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of G49N's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Bernard Gilly (62yo)

8.1yrs

Tenure

€628,518

Compensation

Dr. Bernard Gilly, Ph.D. serves as Chairman at iBionext. He is Independent Chairman at EyeTechCare SA. He serves as President and Chairman of the Board at ChronoLife SAS. He co-founded Fovea Pharmaceutical ...


CEO Compensation Analysis

Compensation vs Market: Bernard's total compensation ($USD680.95K) is above average for companies of similar size in the German market ($USD412.37K).

Compensation vs Earnings: Bernard's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Bernard Gilly
Co-Founder8.1yrs€628.52k2.6% 3.0m
José-Alain Sahel
Scientific Founder0yrsno datano data
Botond Roska
Scientific Founder & Chairman of Scientific Advisory Board0yrsno datano data
Jean Bennett
Scientific Founder & Vice Chairman of Scientific Advisory Board0yrsno datano data
Luk Vandenberghe
Scientific Founder & Member of Scientific Advisory Board7.8yrsno datano data
Serge Picaud
Scientific Founder & Member of Scientific Advisory Board7.8yrsno datano data
Constance Cepko
Scientific Founders & Member of Scientific Advisory Board7.8yrsno datano data
Thomas Gidoin
Chief Financial Officer4.6yrsno data0.60% 694.2k
Julio Benedicto
Vice President of Marketing2.1yrsno datano data
Barrett Katz
Consultant2.3yrsno datano data

3.5yrs

Average Tenure

Experienced Management: G49N's management team is considered experienced (3.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Bernard Gilly
Co-Founder8.1yrs€628.52k2.6% 3.0m
José-Alain Sahel
Scientific Founder0yrsno datano data
Botond Roska
Scientific Founder & Chairman of Scientific Advisory Board0yrsno datano data
Jean Bennett
Scientific Founder & Vice Chairman of Scientific Advisory Board0yrsno datano data
Luk Vandenberghe
Scientific Founder & Member of Scientific Advisory Board7.8yrsno datano data
Serge Picaud
Scientific Founder & Member of Scientific Advisory Board7.8yrsno datano data
Constance Cepko
Scientific Founders & Member of Scientific Advisory Board7.8yrsno datano data
Michael Wyzga
Independent Chairman of the Board3.9yrs€165.35kno data
Peter Goodfellow
Independent Director0yrs€60.00kno data
Ernst Bamberg
Member of Scientific Advisory Board7.8yrsno datano data

7.8yrs

Average Tenure

64yo

Average Age

Experienced Board: G49N's board of directors are considered experienced (7.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.1%.


Top Shareholders

Company Information

GenSight Biologics S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: GenSight Biologics S.A.
  • Ticker: G49N
  • Exchange: DB
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €116.243m
  • Shares outstanding: 32.65m
  • Website: https://www.gensight-biologics.com

Number of Employees


Location

  • GenSight Biologics S.A.
  • 74, rue du Faubourg Saint-Antoine
  • Paris
  • Ile-de-France
  • 75012
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
G49NDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2016
SIGHTENXTPA (Euronext Paris)YesOrdinary SharesFREURJul 2016
0RIMLSE (London Stock Exchange)YesOrdinary SharesGBEURJul 2016
SIGHTPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJul 2016
GSGT.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2016

Biography

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include GS010, an AAV2 based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by mutation of the ND4 gene; and GS030, which is in Phase I/II trial for the treatment of reinitis pigmentosa and dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was founded in 2012 and is headquartered in Paris, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/17 22:34
End of Day Share Price2020/02/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.